Clorox (NYSE:CLX) Stock Rating Upgraded by BNP Paribas

Clorox (NYSE:CLX) was upgraded by analysts at BNP Paribas to a “strong sell” rating in a research report issued on Friday, Zacks.com reports.

CLX has been the subject of several other reports. JPMorgan Chase & Co. reduced their price target on Clorox from $150.00 to $148.00 and set a “neutral” rating for the company in a report on Friday, August 2nd. DA Davidson reissued a “neutral” rating and issued a $153.00 price target on shares of Clorox in a report on Friday. Barclays raised their price target on Clorox from $122.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Citigroup raised their price target on Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a report on Friday. Finally, TD Cowen initiated coverage on Clorox in a report on Tuesday, July 23rd. They issued a “sell” rating and a $122.00 price target for the company. Six analysts have rated the stock with a sell rating and thirteen have given a hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $143.50.

Clorox Trading Up 0.3 %

Shares of CLX stock opened at $165.20 on Friday. The business’s 50 day moving average is $143.55 and its two-hundred day moving average is $142.87. Clorox has a twelve month low of $114.68 and a twelve month high of $166.49. The company has a market capitalization of $20.46 billion, a P/E ratio of 85.60, a price-to-earnings-growth ratio of 3.34 and a beta of 0.40. The company has a current ratio of 1.03, a quick ratio of 0.63 and a debt-to-equity ratio of 5.04.

Clorox (NYSE:CLX) last announced its earnings results on Thursday, August 1st. The company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.28. Clorox had a return on equity of 281.12% and a net margin of 3.95%. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. Equities analysts forecast that Clorox will post 6.56 EPS for the current year.

Hedge Funds Weigh In On Clorox

A number of institutional investors have recently made changes to their positions in the stock. Heritage Wealth Management Inc. purchased a new stake in shares of Clorox in the second quarter valued at $283,000. Sanctuary Advisors LLC purchased a new stake in shares of Clorox in the second quarter valued at $2,964,000. Birmingham Capital Management Co. Inc. AL grew its position in shares of Clorox by 3.8% in the second quarter. Birmingham Capital Management Co. Inc. AL now owns 8,602 shares of the company’s stock valued at $1,174,000 after purchasing an additional 311 shares during the period. SPC Financial Inc. grew its position in shares of Clorox by 2.2% in the second quarter. SPC Financial Inc. now owns 3,485 shares of the company’s stock valued at $476,000 after purchasing an additional 75 shares during the period. Finally, Wallace Capital Management Inc. grew its position in shares of Clorox by 1.4% in the second quarter. Wallace Capital Management Inc. now owns 13,354 shares of the company’s stock valued at $1,822,000 after purchasing an additional 180 shares during the period. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.